Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income

Stoke Therapeutics

03/08/2026 21:11

Overview
US biotechnology firm's Q2 revenue fell but beat analyst expectations
Net loss widened yr/yr, reflecting higher R&D and launch readiness expenses
Q2 revenue declined yr/yr due to lower collaboration and licensing revenue

Outlook
Company expects Phase 3 data readout for zorevunersen in Dravet syndrome in Q3 2027
Stoke plans to initiate rolling U.S. NDA submission for zorevunersen in Q1 2027
Initial safety and efficacy data for STK-002 in ADOA anticipated in H1 2027

Result Drivers
LOWER COLLABORATION REVENUE - Q2 revenue declined yr/yr due to reduced collaboration and licensing revenue, notably the absence of a large Biogen IP license recognition
HIGHER R&D EXPENSES - Research and development expenses increased due to expanded activities and personnel costs supporting zorevunersen advancement
LAUNCH READINESS COSTS - Sales, general and administrative expenses rose, reflecting growth in personnel and launch readiness expenses

Company press release: ID:nBw3wzPPYa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$9.33 mln
$6.04 mln (9 Analysts)
Q2 Loss Per Share
 
$0.93
 
Q2 Net Loss
 
$61.62 mln
 
Q2 Operating Expenses
 
$74.75 mln
 
Q2 Operating Income
 
-$65.43 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Stoke Therapeutics Inc is $44.00, about 52.5% above its July 31 closing price of $28.86

Reuters Recommended Reads
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
Aug 3 - Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spending
Aug 3 - Curium strikes up to $8 bln deal for radiopharma peer Lantheus

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)